View in EDS HTML Full Text PDF Full Text

Effectiveness and safety of the recombinant zoster vaccine in adults aged ≥50 years with inflammatory bowel disease.

Saved in:
Bibliographic Details
Title: Effectiveness and safety of the recombinant zoster vaccine in adults aged ≥50 years with inflammatory bowel disease.
Authors: Tseng HF; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.; Department of Health System, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA., Sy LS; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Rayens E; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Ackerson BK; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Ku JH; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Wu J; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Luo Y; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Cheng Y; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Patel AR; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Solano Z; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., De Jesus J; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Amundsen B; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Florea A; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Chmielewski-Yee E; Vaccines and Infectious Disease Epidemiology, GSK, Rockville, MD, USA., Oraichi D; Real World Biostatistics, GSK, Rockville, MD, USA., Seifert H; Global Safety, GSK, Rockville, MD, USA., Yun H; Vaccines and Infectious Disease Epidemiology, GSK, Rockville, MD, USA., Qian L; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2025 Dec; Vol. 21 (1), pp. 2576981. Date of Electronic Publication: 2025 Dec 08.
Publication Type: Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41359345
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Effectiveness and safety of the recombinant zoster vaccine in adults aged ≥50 years with inflammatory bowel disease.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Tseng+HF%22">Tseng HF</searchLink>; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.; Department of Health System, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.<br /><searchLink fieldCode="AU" term="%22Sy+LS%22">Sy LS</searchLink>; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.<br /><searchLink fieldCode="AU" term="%22Rayens+E%22">Rayens E</searchLink>; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.<br /><searchLink fieldCode="AU" term="%22Ackerson+BK%22">Ackerson BK</searchLink>; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.<br /><searchLink fieldCode="AU" term="%22Ku+JH%22">Ku JH</searchLink>; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wu+J%22">Wu J</searchLink>; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.<br /><searchLink fieldCode="AU" term="%22Luo+Y%22">Luo Y</searchLink>; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.<br /><searchLink fieldCode="AU" term="%22Cheng+Y%22">Cheng Y</searchLink>; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.<br /><searchLink fieldCode="AU" term="%22Patel+AR%22">Patel AR</searchLink>; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.<br /><searchLink fieldCode="AU" term="%22Solano+Z%22">Solano Z</searchLink>; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.<br /><searchLink fieldCode="AU" term="%22De+Jesus+J%22">De Jesus J</searchLink>; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.<br /><searchLink fieldCode="AU" term="%22Amundsen+B%22">Amundsen B</searchLink>; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.<br /><searchLink fieldCode="AU" term="%22Florea+A%22">Florea A</searchLink>; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.<br /><searchLink fieldCode="AU" term="%22Chmielewski-Yee+E%22">Chmielewski-Yee E</searchLink>; Vaccines and Infectious Disease Epidemiology, GSK, Rockville, MD, USA.<br /><searchLink fieldCode="AU" term="%22Oraichi+D%22">Oraichi D</searchLink>; Real World Biostatistics, GSK, Rockville, MD, USA.<br /><searchLink fieldCode="AU" term="%22Seifert+H%22">Seifert H</searchLink>; Global Safety, GSK, Rockville, MD, USA.<br /><searchLink fieldCode="AU" term="%22Yun+H%22">Yun H</searchLink>; Vaccines and Infectious Disease Epidemiology, GSK, Rockville, MD, USA.<br /><searchLink fieldCode="AU" term="%22Qian+L%22">Qian L</searchLink>; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101572652%22">Human vaccines & immunotherapeutics</searchLink> [Hum Vaccin Immunother] 2025 Dec; Vol. 21 (1), pp. 2576981. <i>Date of Electronic Publication: </i>2025 Dec 08.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101572652 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2164-554X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221645515%22">21645515 </searchLink><i>NLM ISO Abbreviation: </i>Hum Vaccin Immunother <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41359345
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/21645515.2025.2576981
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2576981
    Titles:
      – TitleFull: Effectiveness and safety of the recombinant zoster vaccine in adults aged ≥50 years with inflammatory bowel disease.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Tseng HF
      – PersonEntity:
          Name:
            NameFull: Sy LS
      – PersonEntity:
          Name:
            NameFull: Rayens E
      – PersonEntity:
          Name:
            NameFull: Ackerson BK
      – PersonEntity:
          Name:
            NameFull: Ku JH
      – PersonEntity:
          Name:
            NameFull: Wu J
      – PersonEntity:
          Name:
            NameFull: Luo Y
      – PersonEntity:
          Name:
            NameFull: Cheng Y
      – PersonEntity:
          Name:
            NameFull: Patel AR
      – PersonEntity:
          Name:
            NameFull: Solano Z
      – PersonEntity:
          Name:
            NameFull: De Jesus J
      – PersonEntity:
          Name:
            NameFull: Amundsen B
      – PersonEntity:
          Name:
            NameFull: Florea A
      – PersonEntity:
          Name:
            NameFull: Chmielewski-Yee E
      – PersonEntity:
          Name:
            NameFull: Oraichi D
      – PersonEntity:
          Name:
            NameFull: Seifert H
      – PersonEntity:
          Name:
            NameFull: Yun H
      – PersonEntity:
          Name:
            NameFull: Qian L
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2025 Dec
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2164-554X
          Numbering:
            – Type: volume
              Value: 21
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Human vaccines & immunotherapeutics
              Type: main
ResultId 1